Michael Celano News Today

BALA CYNWYD, Pa., Feb. 16, 2024 -- Larimar Therapeutics, Inc. , a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of...

Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Rating) CFO Michael Celano purchased 5,000 shares of the stock in a transaction dated Wednesday, May 17th. The stock was bought at an average cost of $3.73 per share, with a total value of $18,650.00. Following the completion of the purchase, the chief financial officer now owns 112,746 shares […]

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trials 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreichs Ataxia and First Quarter 2023... | May 15, 2023

Executive appointments, promotions, and departures in omics and molecular diagnostics for the week of Aug. 8, 2022.

BETHLEHEM, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, today announced that Carrie

Board Continues Search for Permanent CEO Evaluation of Strategic Alternatives Ongoing BETHLEHEM, Pa., March 22, 2022 (GLOBE NEWSWIRE) --...

Board Continues Search for Permanent CEO

Share: BALA CYNWYD, Pa., May 25, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreichs ataxia (FA) and other complex rare diseases, today announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on the CTI-1601 clinical program and that the company will not be closing a previously announced private placement financing. CTI-1601 is a recombinan...

Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results May 10, 2021 16:05 ET | Source: Larimar Therapeutics Larimar Therapeutics Bala Cynwyd, UNITED STATES - Topline data from placebo-controlled Phase 1 program in Friedreichs ataxia patients to be announced tomorrow, May 11, 2021- Management to discuss during webcast and conference call at 8 a.m. ET - Cash and investments of $81.4 million as of March 31, 2021 BALA CYNWYD, Pa....

Published: Mar 04, 2021 Reported preliminary Phase 1 findings from a Single Ascending Dose (SAD) trial that suggest single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg in Friedreichs ataxia (FA) patients Cash and investments of $92.6 million as of December 31, 2020 BALA CYNWYD, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex ...